Latest Conference Coverage

The Promise of Personalized Neurostimulation in Slowing Alzheimer Progression: Giacomo Koch, MD, PhD; Ken Mariash; Emiliano Santarnecchi, PhD

A trio of experts from Sinaptica Therapeutics talked about recent findings presented at CTAD 2024 from a study assessing personalized transcranial magnetic stimulation in patients with Alzheimer disease. [WATCH TIME: 5 minutes]

NeuroVoices: Richard Nowak, MD, MS, on the MINT Trial of Inebilizumab in Myasthenia Gravis

The director of the myasthenia gravis clinic at Yale University discussed the therapeutic potential of inebilizumab, an FDA-approved treatment for NMOSD, in myasthenia gravis, based on data from the phase 3 MINT study.

Addressing Treatment Gaps in Adolescents With Myasthenia Gravis: Jonathan Strober, MD

The director of the Muscular Dystrophy Clinic at UCSF Benioff Children’s Hospital provided insight on promising data from the phase 2/3 VIBRANCE-MG study assessing investigational nipocalimab in adolesents with myasthenia gravis. [WATCH TIME: 3 minutes]

Pepinemab Produces Positive Effects on Plasma Biomarkers and Cognitive Measures in Phase 1b/2 SIGNAL-AD Trial

SIGMAR1 Activating Agent Blarcamesine Meets Pre-Specified Efficacy in Phase 2/3 Trial of Alzheimer Disease

Over a 48-week treatment period, once daily blarcamesine slowed clinical decline in patients with early-stage Alzheimer disease, with even more pronounced effects in pre-specified common SIGMAR1 wild type group.

Latest Brainshuttle AD Study Interim Data Support Continued Trontinemab Development for Alzheimer Disease

At week 25 of treatment with trontinemab, patients demonstrated decreases in CSF total tau, CSF p-tau181, and CSF neurogranin.

Enhancing Diversity and Accessibility in Clinical Trials for Alzheimer Disease: Jessica Langbaum, PhD

The senior director of research strategy at Banner Alzheimer’s Institute talked about improving clinical trial diversity through removal of logistical barriers, creating inclusive outreach strategies, and designing trials that address the unique needs of underrepresented populations. [WATCH TIME: 5 minutes]

Marking a New Era in Patient Care With Advancements in Disease-Modifying Alzheimer Treatments: Alireza Atri, MD, PhD

The director of the Banner Sun Health Research Institute talked about how the newly approved Alzheimer treatments have shown promise in slowing clinical decline, signaling a foundational shift toward disease-modifying therapies that target core biological processes. [WATCH TIME: 5 minutes]

The High Cost of Innovation: Navigating Rising Drug Prices in Neurology

Amy Tsou, MD, MSc, program director at the National Institutes of Neurological Disorders and Stroke, discussed the increasing cost of prescription drugs in the US and its impact on healthcare providers, including those who treat patients with neurologic conditions.

Alzheimer Agitation Therapy Brexpiprazole Maintains Safe Profile in Longitudinal Analysis

Over a 24-week period, comprising both the core study and extension trial, the incidence of treatment-emergent adverse events was infrequent, with less occurring over the long-term extension.

The Arctic Mutation, Treatment Innovations, and Early Diagnosis Imperatives in Alzheimer: Lars Lannfelt, MD, PhD

The professor of molecular geriatrics at Uppsala University talked about the research journey that led to the development of targeted antibody therapies for Alzheimer disease and emphasized the need for early diagnosis. [WATCH TIME: 5 minutes]

Enhanced Dosing of Donanemab Lowers ARIA Risk, Anti-Tau Agent E2814 Shows Promising Results, Combination Approach of Intranasal Insulin and Empagliflozin

Neurology News Network. for the week ending November 2, 2024. [WATCH TIME: 4 minutes]

The Promise of Cannabinoid Therapy for Agitation in Advanced Alzheimer Disease: Brent Forester, MD, MSc

The chair of psychiatry at Tufts University School of Medicine talked about a recent study that suggested synthetic tetrahydrocannabinol could reduce agitation in patients with advanced Alzheimer disease. [WATCH TIME: 5 minutes]

Acumen Pharmaceuticals’ Phase 2 Advancements in Alzheimer Disease Screening: Todd Feaster, PsyD

The senior clinical research scientist at Acumen Pharmaceuticals talked about the company's approach to refining Alzheimer screening by implementing plasma p-tau 217 biomarkers. [WATCH TIME: 5 minutes]

Episode 127: Adapting Neuromuscular and Electrodiagnostic Medicine Education for Modern Learners

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Lawrence Robinson, MD. [LISTEN TIME: 15 minutes]

Alzheimer Gene Therapy LX1001 Demonstrates Dose-Dependent Increase in APOE2 Expression

LX1001, an AAV gene therapy, was considered safe and well tolerated, with no events of amyloid-related imaging abnormalities (ARIA) observed.

Refining Alzheimer Treatment Through Biomarker-Based Patient Selection: Michael Woodward, MD, FRACP; Anthony Caggiano, MD, PhD

The head of dementia research at Austin Health and the chief medical officer at Cognition Therapeutics talked about recently presented phase 2 findings on CT1812, an investigational medicine for patients with mild to moderate Alzheimer disease, at CTAD 2024. [WATCH TIME: 5 minutes]

Screening Experience of Phase 2 Autonomy Study Provides Insights for Anti-Tau Trials in Alzheimer Disease

In total, more than half of the screened population failed by not meeting plasma p-tau217 criteria and of the remaining, most participants were not in the intermediate tau PET range.

The Role of Monoclonal Antibodies and Emerging Combination Treatments to Expand Alzheimer Therapeutics: Howard Fillit, MD

The cofounder and chief science officer of the Alzheimer's Drug Discovery Foundation talked about how Alzheimer disease treatment may evolve through combination therapies, adding potential anti-tau and anti-inflammatory agents to improve patient outcomes. [WATCH TIME: 5 minutes]

Intranasal Insulin and Empagliflozin Demonstrate Therapeutic Potential as Combination Treatment for Alzheimer Disease

Insulin treatment significantly increased beneficial plasma biomarkers, including SNAP25, SMOC1, BDNF, and VCAM1.

Using Biomarker Testing to Advance Alzheimer Diagnostics: Margherita Carboni, PhD

The indication lead of neurology at Roche Diagnostics International talked about the latest Alzheimer biomarkers that are aimed to transform diagnostic accuracy and accessibility as well as enhance early detection and treatment. [WATCH TIME: 5 minutes]

Identifying Small Clinical Characteristics to Facilitate Early Myasthenia Gravis Diagnosis: Judith Thompson, PharmD, MPH, CPHQ

The rare disease population health strategy lead at UCB provided clinical insight on some of the unique challenges of diagnosing myasthenia gravis, and some of the early signs clinicians and non-specialists should look out for. [WATCH TIME: 3 minutes]

Phase 3 TRAILRUNNER-ALZ 3 to Test Effects of IgG1 Monoclonal Antibody Remternetug in Early Alzheimer Disease

The multicenter, randomized, double-blind, placebo-controlled, parallel-group, event-driven trial will use time to clinical progression, defined as an increase in Clinical Dementia Rating score, as the primary end point.

Promising Innovative Gene Therapy for APOE4 Homozygous Alzheimer Disease: R. Nolan Townsend; Sandi See Tai, MD; Kim G. Johnson, MD

A trio of experts talked about Lexeo Therapeutics’ LX1001 gene therapy trial that demonstrated promising safety and biomarker effects in patients with early-stage Alzheimer disease. [WATCH TIME: 5 minutes]

Advancing Alzheimer Treatment Through Gamma Oscillation Stimulation: Ralph Kern, MD, MHSc

The chief medical officer at Cognito Therapeutics talked about a medical device designed to slow cognitive decline in patients with Alzheimer disease through gamma frequency brain stimulation. [WATCH TIME: 6 minutes]

Risk of ARIA-E in Donanemab Attenuated Through New Enhanced Titration Method of Delivery

Compared with the standard dosing arm, those on an enhanced titration dosing of donanemab demonstrated a 41% reduction in the relative risk of ARIA-E.

Anti-Tau Agent E2814 Shows Impact on Early and Late Tau Biomarkers, Further Supporting Development

Despite a small cohort sample size, treated patients with E2814 demonstrated significant reductions in p-tau217 after 12 weeks of treatment, sustained through the 108-week time point.

AAV Vectors in Gene Therapy: Overcoming Barriers for Muscular Dystrophy Treatment

The Significance of Gene Therapy in Neuromuscular Medicine at the 2025 MDA Conference: Paul Melmeyer, MPP

Prior to the 2025 MDA Conference, the vice president of Public Policy & Advocacy at the Muscular Dystrophy Association talked about the increasing interest in gene therapy in the field of neuromuscular diseases.

Investigational Nipocalimab Demonstrates Efficacy and Safety in Adolescent Population of Myasthenia Gravis

In a small sample population of adolescents with myasthenia gravis, nipocalimab met its primary end point, showing a significant reduction in total serum immunoglobuin over a 24-week period.